Max Ma,
Director, Medical Affairs
Dr. Ma joined Roche in 2008 and held a number of positions with increasing responsibility in various business areas. He joined Genentech as an Oncology Biomarker Scientist discovering predictive biomarkers for various targeted therapies. In 2011, he moved to Roche Diagnostics as a team lead in Roche Molecular Diagnostics (RMD) developing oncology IVD assays. Early 2016, he joined Roche Sequencing Solutions (RSS), devoting his effort to building oncology sequencing assays and conducting clinical research after launching AVENIO assays globally. Max holds a PhD in Biochemistry from the University of Rochester, New York, followed by his postdoctoral training in Cancer Biology at Harvard Medical School. Dr. Max holds multiple patents on molecular technologies and publishes as a lead author in prestigious journals including EMBO, Nature Reviews and Cell.
|
|
|
